A Class 1 recall of Medtronic's Quick-Set Insulin Infusion sets was announced by the FDA (July 10, 2009), after it was discovered that 60,000 out of 3 million sets could deliver an incorrect dose of insulin, resulting in possible death. Recall was based on a manufacturing defect.
Houston, TX, USA, December 2, 2009 (PRESSbooth.ORG) -- The U.S. Food and Drug Administration (FDA) announced on July 10, 2009 that Medtronic, Inc. issued a Class I recall of their Quick-Set® Insulin Infusion sets due to a manufacturing defect. Medtronic estimated that at least 60,000 out of 3 million infusion sets could be affected. An infusion set is a thin plastic tube used to deliver a correct dose of insulin from an insulin pump to a diabetes patient and is typically replaced every three days. The recalled infusion sets are used with MiniMed Paradigm Insulin Pumps.
Medtronic explained that there was a defect in the manufacture of the tubing used in the Quick-Set® infusion set, referred to as “Lot 8,” which may not allow the insulin pump to vent air pressure properly. This could result in the delivery of too much or too little insulin and can cause serious injury or death.
Houssiere, Durant & Houssiere, LLP’s research shows that doctors treating diabetes state that too little insulin causes patients' blood glucose level to rise, resulting in frequent urination, muscle stiffness, aching, nausea and dizziness. If uncorrected, the blood sugar can rise to a dangerously high (hyperglycemic) level resulting in Ketoacidosis, coma and death.
On the other hand, over delivery of insulin may cause patients to experience a condition known as hypoglycemia (low blood sugar), equally as serious. Doctors report that low blood sugar can result in confusion, fainting, dizziness, difficulty speaking, sweating, weakness and hunger. Severe hypoglycemia can lead to seizures, coma or even death. Houssiere, Durant & Houssiere, LLP’s research is based on findings from medical doctors who treat diabetes.
Houssiere, Durant & Houssiere, LLP is filing suite in federal court in Houston, Texas on behalf of six injured plaintiffs.
About Houssiere, Durant & Houssiere, LLP:
Houssiere, Durant & Houssiere, LLP is actively investigating this reported defect and its results to patients and clients. Further information may be obtained from Houssiere, Durant & Houssiere, LLP 1990 Post Oak Blvd., Suite 800, Houston, Texas 77056 or by calling (888) 881-8100. You should maintain any unused infusion sets.
Contact:
Stephanie Brundage
Phone: 713-626-3700
Email: sbrundage @ hdhtex.com
:: 
:: 
::
